Booking Health has released findings on how international patients can access personalized dendritic cell therapy for glioblastoma in Germany. A Canadian couple's journey highlights the differences in treatment availability and patient support between Canada and Germany, showcasing the potential for improved outcomes through cross-border healthcare options.

• 01Ron, a Canadian patient, was diagnosed with grade 4 glioblastoma and faced limited treatment options under the Canadian healthcare system.
• 02Freya, Ron's wife, discovered that Germany offers personalized dendritic cell therapy outside of clinical trials, which is not available in Canada.
• 03The therapy involves training the immune system to target tumors, resulting in fewer side effects compared to traditional chemotherapy.
• 04Booking Health facilitated Ron's treatment in Germany by coordinating logistics, medical translations, and providing a patient coordinator.
• 05After treatment, Ron's tumor showed significant reduction, contrasting with the stabilization expected from Canadian treatments.

The findings emphasize the importance of access to innovative treatments for glioblastoma patients, potentially influencing healthcare policies and patient choices in Canada.